FDA Urges Painkiller Opana Removal
FDA Urges Endo Internation To Cease Sales of Opana
July 10, 2017
The Irish drug manufacturer Endo International has, at the urging of the U.S. Food and Drug Administration (FDA), agreed to cease all sales of its narcotic painkiller Opana. The FDA has linked Opana to drug abuse and injection-related diseases.
Opana is Endo’s trade name for oxymorphone hydrochloride, a drug whose abusers frequently inject because it is resistant to crushing and snorting. Injection of the drug has been associated with a rise in HIV and hepatitis C, which can be transmitted by dirty needles.
The FDA had asked Endo one month ago to withdraw from the market a reformulated version of Opana. Though Endo issued a statement in which it asserted that it still believes the drug is safe and effective, the company complied with the FDA’s request.
This marks the first time that the FDA has moved to stop sales of a prescription opioid medication for reasons having to do with the risks of abuse. Opana is on the list of drugs that have been implicated in the deaths of more than 30,000 Americans in what has come to be known as the opioid epidemic.
Last year, Endo earned nearly $160 million from sales of Opana.
The FDA has repeatedly stated that makers of opioid medications must take greater steps to formulate their drugs to include abuse-deterrent technologies.
If you or a loved one has fallen victim to the opioid epidemic, the expert attorneys at TheLawFirm.com may be able to help you. Contact us for a free consultation.
TheLawFirm.com’s award winning lawyers have been featured in over 50 radio and television interviews including:
Real lawyers, real results!
no recovery, no fee!